


O. Agbo, C. Sansac, M.P. Ponrouch, I. Roch-Torreilles, J.L. Allaz, P. Rambourg.
CHRU de Montpellier, Hérault, Montpellier, France.

Omalizumab

MECHANISM OF ACTION



THERAPEUTIC USE

In France, the omalizumab marketing authorisation is **only approved in case of severe persistent allergic asthma**. However, literature shows some utilisations in treatments for chronic urticaria.

Cold urticaria refers to a group of urticarial manifestations induced by cold exposure. As a group, it represents 3-5% of all physical urticarias.

Objectives

We report the use of omalizumab in order to treat a patient suffering a **chronic cold urticaria resistant** to conventional treatments.

Materials and method


This is a retrospective study based on the medical file of the patient. We have observed his clinical status before and after treatment beginning.

The patient :

- 67 years old man
- 90 kg

Problem :
Chronic urticaria for over 30 years.

Pre-treatment :
Serum IgE level : 556,7 IU/mL



The disease was disclosed by a pressure urticaria, which had been neglected for a long time. It then turned into a **cold urticaria in the 90's**.


The latter showed itself in 2002 as the patient experienced an anaphylactic shock in a bath at 24 °C.

Results

This status has been evaluated by auto-evaluation, life quality tests and ice's test.

Several lines of treatment were tested on the patient: *high H1 antihistamine dose, montelukast, methotrexate, anakinra*. **ALL UNSUCCESSFUL**.

In view of this therapeutic impasse, **omalizumab appeared as an alternative**. The best frequency of administration and the best dosage were investigated.



Discussion / Conclusion

Omalizumab do not have a marketing authorisation for this indication. In view of the results obtained for this patient, **Omalizumab appears to be an alternative for treating chronic urticaria** in treatment failure.

Indeed, it is well tolerated, the **risk-benefit ratio is positive for this patient**. Randomized studies of safety and efficacy should be conducted to confirm its safety.

The only problem is the cost incurred for such care.